Gyros Protein Technologies’ Post

“It’s a scientist’s dream to have something you worked on be approved.” – Dr. Nina E. Weisser, Director, Multispecific Antibody Therapeutics at Zymeworks. Nina shares the journey of innovation, teamwork, and dedication in the development of our recent FDA-approved therapy designed with our Azymetric™  platform. This milestone is a testament to the incredible passion and collaboration of our team as we strive to make a meaningful difference in the lives of patients with difficult-to-treat diseases.. Watch the story and join us in celebrating this milestone! #Biotech #Innovation

Did you miss it? Last month, we introduced our groundbreaking chemical modification search tool! If you are working in oligonucleotide therapeutics, and want to enhance your innovation capabilities, take a look at the link below and explore what this revolutionary tool can do for you! #oligonucleotide #RNA #chemicalmodification #innovation

Thoughts on this? >> RA Capital invests $35M in UK cancer biotech CellCentric >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #biotech #productmarketing

#ICYMI 🔉 Our latest episode of the Back Bay Life Science Report #podcast is live! Join Peter Bak and Christian Thienel as they explore “The Optimism of Bispecific Antibodies” and uncover: ➡️ The biologics of a bispecific antibody and its benefits compared to autologous therapies ➡️ The buzz around Akeso Biopharma and Summit Therapeutics, Inc., PD-1 VEGF bispecific antibody asset ➡️ The broad state of bispecifics in approved products and development pipelines ➡️ The potential of trispecifics, bispecific conjugates and beyond Don’t miss out on this discussion:  https://bit.ly/4enyzcE #Antibodies #Oncology #BBLSA #IndustryInsights #LifeScienceReport #Healthcare #MarketDynamics  

Explore how a faster single-step platform for expressing #antibody fragments is helping to speed up development of antibody therapeutics. https://okt.to/CMpGwe

Thoughts on this? >> Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #productmarketing

Thoughts on this? >> Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #productmarketing #biotech

"Beckman Coulter Life Sciences has unveiled the Cydem VT Automated Clone Screening System, a cutting-edge solution for lab managers seeking to streamline cell line development workflows." Lab Manager reports how our new innovation significantly reduces time to market for biologic drug discovery and monoclonal antibody-based therapeutics: https://becls.co/3DCZFzG #DanaherNews #CellLineDevelopment #mAbs

Thoughts on this? >> Vir’s early T cell engager data offer first look at cancer pivot >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #productmarketing

The authors of this research identify a library of 3-amino-1,2,4-triazine derivatives that inhibit PDK activity and use Enzo’s MITO-ID® Membrane Potential Detection Kit in human pancreatic PSN-1 cells, to further characterize the mechanisms by which they work. They aim to further test these derivative compounds for efficacy as therapeutics against KRAS-mutant pancreatic ductal adenocarcinoma. Read the paper > https://lnkd.in/e8AnhiHN Learn more about Enzo’s product > https://lnkd.in/eTnJyf66 #ScientistsEnablingScientists #drugdiscovery #livecell #cellularassay